Description:
Over the last several years there have been many advances made in the area of myeloproliferative neoplasms (MPN).  In this session, we will review the management of MPNs across the spectrum.  In polycythemia vera (PV) and essential thrombocythemia (ET), management of cytoreductive therapies, and appropriate choice of patient and agent will be reviewed.  In myelofibrosis, there has been an explosion of new treatments.  These new agents attempt to address some of the unmet needs in MF therapy, including thrombocytopenia, anemia, and disease modification.  Newer JAK inhibitors are designed to allow for maximal JAK inhibition even in patients with thrombocytopenia and anemia.  Newer agents are targeting non-canonical pathways that may impact disease biology.  Finally, there have been advances in the understanding of allogeneic stem cells for myelofibrosis, which will be reviewed, including challenges pre-, peri- and post-transplant management.